Kan Li

3.6k total citations · 3 hit papers
60 papers, 1.8k citations indexed

About

Kan Li is a scholar working on Oncology, Epidemiology and Obstetrics and Gynecology. According to data from OpenAlex, Kan Li has authored 60 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Oncology, 14 papers in Epidemiology and 14 papers in Obstetrics and Gynecology. Recurrent topics in Kan Li's work include Endometrial and Cervical Cancer Treatments (14 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Colorectal and Anal Carcinomas (6 papers). Kan Li is often cited by papers focused on Endometrial and Cervical Cancer Treatments (14 papers), Cancer Immunotherapy and Biomarkers (13 papers) and Colorectal and Anal Carcinomas (6 papers). Kan Li collaborates with scholars based in United States, China and Italy. Kan Li's co-authors include Sheng Luo, Vanessa Samouëlian, Krishnansu S. Tewari, Kosei Hasegawa, Bradley J. Monk, Ronnie Shapira‐Frommer, Domenica Lorusso, Pamela Salman, Mivael Olivera and Vincent Castonguay and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Kan Li

57 papers receiving 1.8k citations

Hit Papers

Pembrolizumab for Persistent, Recurrent, or Metastatic Ce... 2021 2026 2022 2024 2021 2023 2023 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer
    2021 581 citations Nicoletta Colombo, Coraline Dubot et al. profile →
  2. Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial
    2023 213 citations Yelena Y. Janjigian, Akihito Kawazoe et al. The Lancet profile →
  3. First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826
    2023 100 citations Bradley J. Monk, Nicoletta Colombo et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Kan Li United States 20 743 414 383 344 340 60 1.8k
Mahdi Fallah Germany 26 1.1k 1.4× 323 0.8× 79 0.2× 720 2.1× 424 1.2× 82 2.6k
Rakesh Gaur United States 17 901 1.2× 94 0.2× 215 0.6× 336 1.0× 215 0.6× 39 1.6k
Whitfield B. Growdon United States 31 616 0.8× 384 0.9× 921 2.4× 233 0.7× 582 1.7× 139 2.7k
Rohini Hawaldar India 19 1.1k 1.5× 230 0.6× 242 0.6× 419 1.2× 866 2.5× 55 2.4k
Mahmut Gümüş Türkiye 27 2.2k 3.0× 862 2.1× 453 1.2× 1.2k 3.4× 757 2.2× 174 3.7k
Gideon Zamba United States 19 454 0.6× 219 0.5× 133 0.3× 159 0.5× 249 0.7× 47 1.3k
Jonathan D. Tward United States 24 448 0.6× 225 0.5× 148 0.4× 775 2.3× 732 2.2× 120 2.2k
Anders Mattsson Sweden 30 580 0.8× 206 0.5× 236 0.6× 285 0.8× 303 0.9× 45 3.5k
Brigitte Trétarre France 29 972 1.3× 564 1.4× 51 0.1× 527 1.5× 385 1.1× 122 2.5k
Audrey Mauguen United States 27 785 1.1× 218 0.5× 122 0.3× 509 1.5× 185 0.5× 111 2.1k

Countries citing papers authored by Kan Li

Since Specialization
Citations

This map shows the geographic impact of Kan Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kan Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kan Li more than expected).

Fields of papers citing papers by Kan Li

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kan Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kan Li. The network helps show where Kan Li may publish in the future.

Co-authorship network of co-authors of Kan Li

This figure shows the co-authorship network connecting the top 25 collaborators of Kan Li. A scholar is included among the top collaborators of Kan Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kan Li. Kan Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yin, Hang, et al.. (2025). Generative Video Semantic Communication via Multimodal Semantic Fusion With Large Model. IEEE Transactions on Vehicular Technology. 75(1). 1701–1706. 1 indexed citations
2.
3.
Nakashima, Masayuki, Kan Li, Qichen Chen, et al.. (2023). Appropriate dose of regorafenib based on body weight of colorectal cancer patients: a retrospective cohort study. BMC Cancer. 23(1). 1268–1268. 2 indexed citations
4.
5.
Chen, Qichen, Kan Li, Kristen E. Rhodin, et al.. (2023). Impact of primary tumor resection and metastasectomy among gastroentero-pancreatic neuroendocrine tumors with liver metastases only on survival. HPB. 26(1). 125–136. 1 indexed citations
6.
Monk, Bradley J., Nicoletta Colombo, Krishnansu S. Tewari, et al.. (2023). First-Line Pembrolizumab + Chemotherapy Versus Placebo + Chemotherapy for Persistent, Recurrent, or Metastatic Cervical Cancer: Final Overall Survival Results of KEYNOTE-826. Journal of Clinical Oncology. 41(36). 5505–5511. 100 indexed citations breakdown →
7.
Chen, Qichen, Kan Li, Kristen E. Rhodin, et al.. (2023). Primary tumor resection improves survival of gastrointestinal neuroendocrine carcinoma patients with nonresected liver metastases. Journal of Surgical Oncology. 127(6). 945–955. 1 indexed citations
8.
Li, Huiyue, Jennifer K. Plichta, Kan Li, et al.. (2023). Impact of HER2-low status for patients with early-stage breast cancer and non-pCR after neoadjuvant chemotherapy: a National Cancer Database Analysis. Breast Cancer Research and Treatment. 204(1). 89–105. 10 indexed citations
9.
10.
Janjigian, Yelena Y., Akihito Kawazoe, Yuxian Bai, et al.. (2023). Pembrolizumab plus trastuzumab and chemotherapy for HER2-positive gastric or gastro-oesophageal junction adenocarcinoma: interim analyses from the phase 3 KEYNOTE-811 randomised placebo-controlled trial. The Lancet. 402(10418). 2197–2208. 213 indexed citations breakdown →
11.
Colombo, Nicoletta, Coraline Dubot, Domenica Lorusso, et al.. (2022). Pembrolizumab for Persistent, Recurrent, or Metastatic Cervical Cancer. Obstetrical & Gynecological Survey. 77(1). 30–31. 10 indexed citations
12.
Grantz, Kyra H., Derek A. T. Cummings, Shanta M. Zimmer, et al.. (2021). Age-specific social mixing of school-aged children in a US setting using proximity detecting sensors and contact surveys. Scientific Reports. 11(1). 2319–2319. 7 indexed citations
13.
Li, Kan & Sheng Luo. (2018). Bayesian functional joint models for multivariate longitudinal and time-to-event data. Computational Statistics & Data Analysis. 129. 14–29. 11 indexed citations
14.
Li, Kan, Shuai Yuan, William Yang Wang, et al.. (2018). Periodic benefit-risk assessment using Bayesian stochastic multi-criteria acceptability analysis. Contemporary Clinical Trials. 67. 100–108. 5 indexed citations
15.
Liu, Xiangqi, Xiaomei Lao, Lizhong Liang, et al.. (2017). Neck observation versus elective neck dissection in management of clinical T1/2N0 oral squamous cell carcinoma: a retrospective study of 232 patients. Chinese Journal of Cancer Research. 29(3). 179–188. 13 indexed citations
16.
Csencsits‐Smith, Keri, et al.. (2016). Serum Lymphocyte-Associated Cytokine Concentrations Change More Rapidly over Time in Multiple System Atrophy Compared to Parkinson Disease. NeuroImmunoModulation. 23(5-6). 301–308. 23 indexed citations
17.
Bloudek, Lisa, et al.. (2013). Cost-effectiveness of onabotulinumtoxinA for prophylaxis of headaches in adults with chronic migraine in Canada. Value in Health. 16(3). A105–A105. 2 indexed citations
18.
Li, Wenyuan, et al.. (2012). Geology, geochemistry and genesis of the Lashuixia Ni-Cu deposit in Hualong area, Qinghai Province. Dizhi tongbao. 31(5). 763–772. 1 indexed citations
19.
Li, Kan. (2012). ID-TIMS zircon U-Pb age of Yulonggou intrusive rocks in southern Qilian Mountain and its geological significance. Dizhi tongbao. 10 indexed citations
20.
Zhang, Zhaowei, et al.. (2012). Geochemical Characteristics of the Lashuixia Basic Complex in Qinhai Province and Its Constraints on Genesis of the Deposit. Geology and Exploration. 48(5). 959–968. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mahdi Fallah Breakdown of academic impact, for papers by Rakesh Gaur Breakdown of academic impact, for papers by Whitfield B. Growdon Breakdown of academic impact, for papers by Rohini Hawaldar Breakdown of academic impact, for papers by Mahmut Gümüş Breakdown of academic impact, for papers by Gideon Zamba Breakdown of academic impact, for papers by Jonathan D. Tward Breakdown of academic impact, for papers by Anders Mattsson Breakdown of academic impact, for papers by Brigitte Trétarre Breakdown of academic impact, for papers by Audrey Mauguen
Rankless by CCL
2026